The meeting will cover the design and optimisation of agents targeting a variety of cancer mechanisms. Individual case studies will examine approaches to oncology drug discovery in areas which will include Hsp90 inhibition, HDAC inhibition, PI3 kinase inhibition and estrogen receptor downregulators.
Explore
Membership
